A clinical trial is only as powerful as its participants. For years, researchers have struggled to fill clinical trials and enroll sufficiently diverse groups of patients for results to reflect the broader population, in part because of stringent guidelines on who can participate.
YourBio Health, Inc., developers of the world's first painless push-button blood collection device, was identified as a key contributor in the recent preprint published report in medRxiv.
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.
The Duke Clinical Research Institute (DCRI) has been named the Clinical Trials Data Coordinating Center for large-scale national research studies aimed at understanding and improving the treatment of long COVID.
MD Anderson and TransCode announced a strategic alliance to advance TransCode's pipeline of RNA-targeted therapeutic and diagnostic candidates for oncology.
Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS 2022, the International AIDS Conference taking place virtually and in person in Montreal, Canada, July 29 to Aug. 2.
The Patient-Centered Outcomes Research Institute (PCORI) has awarded a Georgetown University Medical Center research team led by Dan Merenstein, MD, professor of family medicine at Georgetown’s School of Medicine, $23.6 million in research funding to study treatments for acute rhinosinusitis.
Penn State College of Medicine, in partnership with the American Academy of Family Physicians and DARTNet Institute, will receive a nearly $31 million funding award from the Patient-Centered Outcomes Research Institute (PCORI) to conduct a large-scale, comparative study on asthma therapies for patients 12 and older.
New research in people with a cluster of heart disease risk factors has shown that consuming green tea extract for four weeks can reduce blood sugar levels and improve gut health by lowering inflammation and decreasing “leaky gut.”
MedStar Washington Hospital Center successfully implanted the first dual-chamber leadless pacemaker system in the Baltimore-Washington region this week. Known as the Aveir™ DR Leadless Pacemaker System, this breakthrough technology is being clinically evaluated as part of a worldwide clinical trial sponsored by Abbott, and MedStar Washington Hospital Center was the only hospital in the region selected to participate.
MD Anderson and Obsidian Therapeutics announce FDA clearance of an Investigational New Drug Application for the novel TIL therapy OBX-115, developed under a strategic collaboration. The first-in-human Phase I study will be led at MD Anderson.
With a $45 million grant from the NIH, UC San Diego researchers and collaborators will launch a nationwide clinical trial to further investigate the therapeutic potential of benfotiamine, a synthetic version of thiamine (B1), as a treatment for Alzheimer’s disease.
Stuart Therapeutics, Inc. (Stuart), a clinical stage company headquartered in Stuart, Florida that is developing advanced ophthalmic therapeutics, announced today the results of its Type C Guidance meeting with the U.S. Food and Drug Administration (FDA) regarding the continued development plan for ST-100, Stuart's first drug candidate for the treatment of Dry Eye Disease (DED) in humans.
At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial
Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, according to research from The University of Texas MD Anderson Cancer Center published today in JAMA Oncology.
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking fluticasone furoate for the treatment of mild-to-moderate COVID-19 symptoms.
“Based on these two large trials, it is reasonable to conclude that routine use of fluid boluses during intubation is not beneficial for patients, and ultimately spares them from unnecessary interventions,” says Ochsner Health researcher Vonderhaar.
For men with moderate erectile dysfunction (ED), a noninvasive technique called low-intensity shockwave therapy (LiST) leads to significant improvement in sexual function, concludes a clinical trial in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Elisabeth Gentry had experienced auras ever since she was a toddler, but she didn’t learn that the occasional strange tastes in her mouth and feelings of impending doom were epilepsy until 2015, when she was 15 years old and suffered a grand mal seizure.
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver disease that formerly could only be treated with a liver transplant.
An international team of scientists has identified the neural mechanisms through which sound blunts pain in mice. The findings, which could inform development of safer methods to treat pain, were published in Science.
Under a Defense Advanced Research Projects Agency (DARPA) and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) funded program, a novel COVID-19 antibody delivery approach has advanced to clinical trials.
Outpatient antibiotic management of selected patients with appendicitis is safe, allowing many patients to avoid surgery and hospitalization, and should be considered as part of shared decision-making between doctor and patient.
A new type of vaccine provides protection against a variety of SARS-like betacoronaviruses, including SARS-CoV-2 variants, in mice and monkeys, according to a study led by researchers in the laboratory of Caltech's Pamela Bjorkman, the David Baltimore Professor of Biology and Bioengineering.
COVID-19 vaccines greatly reduced the number of cases of severe COVID-19 disease for everyone regardless of their body size, according to a new study published in The Lancet Diabetes & Endocrinology. Vaccine effectiveness was similar for those with a higher BMI and of a healthy weight, but slightly lower in the underweight group, who were also the least likely to have been vaccinated.
Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center — a member of the global Pacific Pediatric Neuro-Oncology Consortium (PNOC) research group — is participating in a PNOC clinical trial for children and young adults with recurrent or progressive high-grade glioma (HGG), an aggressive, fast-growing type of brain tumor. The hospital is one of only 12 centers in the U.S., and the only center in the New York metropolitan area, to offer this trial.
There is a growing awareness that the design of clinical trials can be misleading and provide evidence that does not end up actually benefiting patients in the clinical setting.
Karallief® Inc., a leading nutraceutical ingredient company that researches, develops, and distributes clinically studied herbal extract ingredient formulas, announced today that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,364,255 for Karallief® Easy Climb®.
DETROIT (June 22, 2022) –Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed completely virtual during the COVID-19 pandemic. The novel study design could serve as a model for future research.Unlike traditional clinical trials that involve in-person clinic visits, researchers in this study engaged directly with more than 400 patients through a mobile app and secure website to collect participants’ data and other information.
An important new study of diverse communities is looking at how brain changes, genetics and other factors contribute to dementia and Alzheimer’s disease. The results could affect millions. Among people 65 and older, about 1 in 9 has Alzheimer’s disease.
New research in mice from Thomas Jefferson University has paved the way for a Phase I clinical trial and has the potential to transform vaccines against HIV and malaria.
According to a paper published in Frontiers in Oncology, daily use of a unique mushroom extract AHCC® supported the immune system in clearing HPV infections in two-thirds of study participants after six months of supplementation.
Daily use of a mushroom extract supported the immune system in clearing human papillomavirus (HPV) infections, according to researchers with UTHealth Houston. The study was published today in Frontiers in Oncology.
New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.
Researchers at The University of Kansas Cancer Center have released the results of a clinical trial that examined the effectiveness of varenicline in African Americans. In their study published in JAMA, African American daily smokers who were given varenicline while receiving counseling had significantly greater quit rates than those who received a placebo.
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.
A team of researchers from National University of Singapore, in collaboration with clinicians from the National University Cancer Institute, Singapore which is part of the National University Health System, has reported promising results in using CURATE.AI, an artificial intelligence tool that identifies and better allows clinicians to make optimal and personalised doses of chemotherapy for patients.
A study of the lead agent (CPI-613) in a class of anticancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and, used in combination, could have efficacy against reducing some tumors.
Previous clinical trials have provided insufficient evidence to decide whether testosterone causes heart problems in men during the first year of treatment, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., and published in The Lancet Healthy Longevity.
Byron Lam and collaborators at the University of Miami reported results from an 8-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy. They found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose.
The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).
New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.
Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
Evolution Research Group, LLC (ERG), a privately held, independent pharmaceutical services provider focused on neuroscience announced the acquisition of Ohio Clinical Trials (OCT), a 64-bed phase 1 unit in Columbus, OH, that specializes in the execution of human abuse potential (HAP) studies, as well as other highly complex early phase trials including pain modeling, qEEG/EEG, respiratory depression, and alcohol interaction, among others.